The role of interferon in polycythemia vera & perspectives on the management of low-risk patients

Richard Silver, MD, Weill Cornell Medical College, New York, NY, comments on the efficacy of interferon (IFN) in comparison to hydroxyurea and phlebotomy in the treatment of patients with low-risk polycythemia vera (PV), explaining the mechanism of action of IFN and highlighting data from several studies. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.